Medical Cannabis for Neuropathic Pain in the UK

Neuropathic pain — pain caused by damage or dysfunction of the nervous system rather than tissue injury — is one of the conditions with the strongest evidence base for cannabis-based medicines in the UK. For patients who have not achieved adequate relief from first-line treatments, a private specialist may prescribe a cannabis-based medicine as part of a broader pain management plan.

What is Neuropathic Pain?

Neuropathic pain is distinct from nociceptive pain (the pain of tissue damage). It arises from injury or disease affecting the somatosensory nervous system — the nerves responsible for processing sensory information including pain, temperature, and touch. Patients typically describe neuropathic pain as burning, shooting, stabbing, or electric-shock-like sensations, often accompanied by allodynia (pain from normally non-painful stimuli such as light touch) and hyperalgesia (heightened pain response).

Common causes of neuropathic pain in the UK include diabetic peripheral neuropathy (nerve damage resulting from poorly controlled blood glucose in type 1 and type 2 diabetes), post-herpetic neuralgia (persistent pain following shingles/herpes zoster), chemotherapy-induced peripheral neuropathy (CIPN, caused by neurotoxic cancer drugs such as taxanes, platinum compounds, and vinca alkaloids), phantom limb pain, and central neuropathic pain associated with multiple sclerosis or spinal cord injury. The burning pain of the feet in diabetic neuropathy and the intense allodynia of post-herpetic neuralgia are two of the most prevalent forms encountered in UK clinical practice.

Standard first-line pharmacological treatments include gabapentin, pregabalin, duloxetine, and amitriptyline — with opioids reserved for cases of inadequate response. Despite optimised pharmacotherapy, a substantial proportion of patients with neuropathic pain are left with ongoing symptoms that meaningfully impair their quality of life, sleep, and daily functioning.

Medical Cannabis and Neuropathic Pain — What Does the Evidence Say?

Neuropathic pain has one of the most established evidence bases among all the conditions for which cannabis-based medicines are prescribed in the UK. Multiple randomised controlled trials and systematic reviews have evaluated cannabinoids in peripheral and central neuropathic pain, with a consistent body of data suggesting that a meaningful proportion of patients experience clinically significant reductions in pain intensity.

THC interacts with CB1 receptors concentrated in the central and peripheral nervous system, modulating pain signal transmission in a manner particularly relevant to neuropathic mechanisms. CBD contributes additional anti-inflammatory and neuromodulatory effects. The combination of these compounds in whole-plant or standardised extracts appears to produce analgesic effects through several complementary pathways.

NICE guidance on chronic pain acknowledges the use of cannabis-based medicinal products in certain pain conditions, and UK specialist prescribers increasingly recognise neuropathic pain as one of the most defensible indications for private cannabis prescribing. UK observational data from real-world prescribing registries further supports neuropathic pain as a condition in which patients frequently report meaningful benefit.

Who Qualifies for a Medical Cannabis Prescription for Neuropathic Pain?

• Confirmed diagnosis: A clinical diagnosis of neuropathic pain, supported by medical records and where applicable by objective testing such as nerve conduction studies or quantitative sensory testing.
• Inadequate response to first-line agents: At least two appropriate pharmacological treatments tried — such as a gabapentinoid (gabapentin or pregabalin) and an antidepressant (amitriptyline or duloxetine) — without adequate relief or with unacceptable side effects.
• Ongoing significant pain: Persistent neuropathic symptoms that continue to impair sleep, daily functioning, or quality of life despite current treatment.
• UK residency and adult age.

What to Expect from a Medical Cannabis Consultation for Neuropathic Pain

At a consultation, the specialist will take a detailed pain history: the character and distribution of the pain, its severity on standardised scales, its impact on sleep and daily activity, and the full pharmacological history of what has been tried. For diabetic neuropathy patients, current glycaemic control is relevant — poorly controlled diabetes can worsen neuropathic pain independently of any treatment.

Products prescribed for neuropathic pain often include THC-containing formulations, given the evidence base specifically supporting THC for this indication. Balanced CBD:THC oils or vaporised flower may be recommended depending on your symptom profile and the specialist's clinical assessment. Titration is gradual, starting at low doses and adjusting based on your reported response and tolerability at follow-up appointments.

How Much Does Medical Cannabis Cost for Neuropathic Pain in the UK?

NHS prescribing of cannabis-based medicines for neuropathic pain remains uncommon in practice. Most patients access treatment through private specialist clinics:

• Initial consultation: £79 to £200.
• Monthly medication: £100 to £400 per month depending on product, dose, and individual requirements.
• Follow-up appointments: £50 to £100 per session, typically every one to three months.

For a full overview of the prescribing process and how to find a UK specialist, see how to get a medical cannabis prescription in the UK. You may also want to review the chronic pain page for information applicable across pain conditions.

Frequently Asked Questions — Medical Cannabis for Neuropathic Pain UK

Is neuropathic pain one of the approved conditions for medical cannabis in the UK?

There is no formal UK "approved list" of conditions. Medical cannabis can be prescribed by a consultant-level specialist for any condition where they judge the clinical benefit to outweigh the risk. Neuropathic pain is one of the most commonly prescribed indications at UK private cannabis clinics, with strong supporting evidence.

Does gabapentin have to fail before I can try medical cannabis?

In practice, UK specialists expect at least two appropriate first-line agents to have been tried without adequate benefit. This typically includes a gabapentinoid and one other first-line agent such as amitriptyline or duloxetine.

Can medical cannabis help with diabetic neuropathy specifically?

Diabetic peripheral neuropathy is one of the most frequently treated forms of neuropathic pain in UK cannabis clinic populations. Observational data from UK prescribing registries includes a large number of patients with diabetic neuropathy, with many reporting meaningful reductions in burning and shooting pain.

Can I drive if I am prescribed cannabis-based medicines for neuropathic pain?

THC-containing products impair driving ability and UK law sets blood-concentration limits. The police can conduct roadside DrugWipe testing. Discuss the implications for driving with your prescribing specialist before starting treatment.

How long does it take for medical cannabis to work for nerve pain?

Vaporised products have an onset of minutes but shorter duration. Oral oils take 30 to 90 minutes to take effect and provide longer-lasting relief. Meaningful assessment of clinical benefit for neuropathic pain typically requires four to eight weeks of carefully titrated dosing.